Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy
MedComm · 2025-10 · 6 (10)
DOI: 10.1002/mco2.70321 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 11.10.2025. Verfasst von Ying Peng und 21 weiteren Autor:innen. Beteiligte Einrichtung: Henan Institute of Medical and Pharmaceutical Sciences Zhengzhou University Zhengzhou Henan China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 334 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite the tremendous amount of basic knowledge in cancer immunity gained and many transitional approaches attempted, current cancer immunotherapies are still far from reaching universal effectiveness. Therefore, next‐generation cancer immunotherapies would emerge from deepened mechanistic insights on the full spectrum of cellular and molecular interactions between cancer cells and their immune sentinels. This review embarks on an exhaustive exploration of the cardinal immunological principles that catalyze robust cancer surveillance and their potential escapes and recapitulate the state‐of‐art understanding of both receptors and corresponding immune cell types involved. Both tumor intrinsic and tumor microenvironmental mediators of immune escapes are outlined in the context of current clinic applications. Following emphasizing the exceptional requisites that effective cancer immunity cycle must meet, specific cellular subsets crucial for igniting tumor immunity, notably effector and helper T cells alongside antigen presentation cells are examined, focusing on their close interactions in both antigen‐dependent and ‐independent manners. Such intricate interactions form dynamic immune hubs at the tumor site, holding promising key functionality in rendering effective cancer retreat. Grounded on these recent insights, refined immunotherapeutic strategies, especially those bolstering priming based anticancer effector functions are advocated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Henan Institute of Medical and Pharmaceutical Sciences Zhengzhou University Zhengzhou Henan China.
- Academy of Military Medical Sciences Institute of Health Service and Transfusion Medicine Beijing China.
- Henan Key Laboratory for Helicobacter Pylori & Microbiota and GI Cancer Marshall Medical Research Center The Fifth Affiliated Hospital of Zhengzhou University Zhengzhou China.
- The Research and Application Center of Precision Medicine The Second Affiliated Hospital of Zhengzhou University Zhengzhou Henan China.
- Department of Immunology School of Basic Medical Sciences Anhui Medical University Hefei Anhui China.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
Zitieren
APA
Peng, Y., Zhan, L., Shi, J., Wang, J., Li, Y., Sun, X., Lv, J., Yang, H., Qiu, Z., Liu, X., Li, C., Gong, S., Jia, W., Wang, H., Zhao, Y., Zhang, B., Guo, W., Guo, J., Shang, J., …, & Gao, F. (2025). Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy. MedComm, 6(10). https://doi.org/10.1002/mco2.70321
Vancouver
Peng Y, Zhan L, Shi J, Wang J, Li Y, Sun X, et al. Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy. MedComm. 2025;6(10). doi:10.1002/mco2.70321
BibTeX
@article{Peng2025,
author = {Peng, Ying and Zhan, Linsheng and Shi, Jianxiang and Wang, Jie and Li, Yueying and Sun, Xiangdong and Lv, Jie and Yang, Huiyu and Qiu, Zan and Liu, Xingzhao and Li, Chenyan and Gong, Shanshan and Jia, Wen and Wang, Huiying and Zhao, Yuqi and Zhang, Bin and Guo, Wei and Guo, Jiancheng and Shang, Jian and Zhou, Qianqian and Yang, Yanan and Gao, Feng},
title = {Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy},
journal = {MedComm},
year = {2025},
volume = {6},
number = {10},
doi = {10.1002/mco2.70321}
}
EUVIMED